Subjective well-being population norms and inequalities in Hungary: a large cross-sectional, internet-based survey
This study aims to provide subjective well-being (SWB) population norms in Hungary and explore the contribution of explanatory factors of SWB inequality among the Hungarian adult general population. (Source: Value in Health)
Source: Value in Health - April 17, 2024 Category: International Medicine & Public Health Authors: Thao T.P. Nguyen, Fanni Rencz, Valentin Brodszky Source Type: research
The Long Coronavirus Disease (COVID) Symptom and Severity Score: Development, Validation, and Application
The primary focus of this research is the proposition of a methodological framework for the clinical application of the long coronavirus disease (COVID) Symptom and Severity Score (LC-SSS). This tool is not just a self-reported assessment instrument developed and validated but serves as a standardized, quantifiable means to monitor the diverse and persistent symptoms frequently observed in individuals suffering from long COVID. (Source: Value in Health)
Source: Value in Health - April 17, 2024 Category: International Medicine & Public Health Authors: Gengchen Ye, Yanan Zhu, Wenrui Bao, Heping Zhou, Jiandong Lai, Yuchen Zhang, Juanping Xie, Qingbo Ma, Zhaoyao Luo, Shaohui Ma, Yichu Guo, Xuanting Zhang, Ming Zhang, Xuan Niu Source Type: research
Cost-effectiveness of axicabtagene ciloleucel for adult patients with relapsed or refractory follicular lymphoma in the United States
The results of a recent single-arm trial (ZUMA-5) of axicabtagene ciloleucel (axi-cel) for relapsed/refractory (r/r) FL demonstrated high rates of durable response and tolerable toxicity among treated patients. To quantify the value of axi-cel compared to standard of care (SOC) to manage r/r FL patients who have had at least two prior lines of systemic therapy (3L+), a cost-effectiveness model was developed from a US third-party payer perspective. (Source: Value in Health)
Source: Value in Health - April 16, 2024 Category: International Medicine & Public Health Authors: Olalekan O. Oluwole, Markqayne D. Ray, Katherine L. Rosettie, Graeme Ball, Jorge Jacob, S. Pinar Bilir, Anik R. Patel, Caron A. Jacobson Source Type: research
Economic Evaluations of CAR-T Cell Therapies for Hematologic and Solid Malignancies: A Systematic Review
This study aims to systematically review evidence on the cost-effectiveness of chimeric antigen receptor (CAR)-T therapies for patients with cancer. (Source: Value in Health)
Source: Value in Health - April 16, 2024 Category: International Medicine & Public Health Authors: Kednapa Thavorn, Emily Thompson, Srishti Kumar, Aliisa Heiskanen, Anubhav Agarwal, Harold Atkins, Risa Shorr, Terry Hawrysh, Kelvin Kar-Wing Chan, Justin Presseau, Daniel A. Ollendorf, Ian D. Graham, Jeremy M. Grimshaw, Manoj Mathew Lalu, Surapon Nochaiwo Tags: Systematic Literature Review Source Type: research
Validating health economic models with the Probabilistic Analysis Check dashBOARD (PACBOARD)
This study aimed to develop and test a generic dashboard to systematically explore the workings of HE models and validate their model parameters and outcomes. (Source: Value in Health)
Source: Value in Health - April 16, 2024 Category: International Medicine & Public Health Authors: Xavier G.L.V. Pouwels, Karel Kroeze, Naomi van der Linden, Michelle M.A. Kip, Hendrik Koffijberg Tags: Methodology Source Type: research
Decision Makers Should Avoid the Health Years in Total (HYT) Approach: A Response to Dr Basu
(Source: Value in Health)
Source: Value in Health - April 15, 2024 Category: International Medicine & Public Health Authors: Mike Paulden, Chris Sampson, James F. O ’Mahony, Eldon Spackman, Christopher McCabe, Jeff Round, Tristan Snowsill Tags: Letter to the Editor Source Type: research
The Inflation Reduction Act: An Opportunity to Accelerate Confidence in US Real-World Evidence.
The objective of this commentary is to explore the implications of the IRA for US pharmaceutical companies, with a specific focus on the role of real-world evidence (RWE) in the context of Medicare reforms. (Source: Value in Health)
Source: Value in Health - April 15, 2024 Category: International Medicine & Public Health Authors: Paul Arora, Alind Gupta, Emma Mackay, Bart Heeg, Kristian Thorlund Source Type: research
It takes two to tango. Setting out the conditions in which performance-based risk-sharing arrangements work for both parties.
Faster regulatory approval processes often fail to achieve faster patient access. We seek an approach, using performance-based risk-sharing arrangements (PBRSA), to address uncertainty for payers regarding the relative effectiveness and value for money of products launched through accelerated approval schemes.One important reason for risk-sharing is to resolve differences of opinion between innovators and payers about a technology ’s underlying value. To date, there has been no formal attempt to set out the circumstances in which risk-sharing can address these differences. (Source: Value in Health)
Source: Value in Health - April 12, 2024 Category: International Medicine & Public Health Authors: Adrian Towse, Elisabeth Fenwick Source Type: research
Utilisation, expenditure, and treatment patterns associated with calcitonin gene-related peptide monoclonal antibodies (CGRP mAbs) reimbursed subject to a managed access protocol in Ireland.
This study presents data on utilisation, expenditure and treatment patterns with CGRP mAbs available under a managed access protocol in Ireland, to a cohort of treatment refractory patients (failed three or more previous treatments) with chronic migraine. (Source: Value in Health)
Source: Value in Health - April 12, 2024 Category: International Medicine & Public Health Authors: Amelia Smith, Karen Finnigan, Sarah Clarke, Michael Barry, Claire Gorry Source Type: research
A Systematic Review and Quality Assessment of Cardiovascular Disease-Specific Health Related Quality of Life Instruments Part I: Instrument Development and Content Validity
This study aimed at systematically identifying and assessing the content validity of CVD-specific HRQoL instruments in clinical studies. (Source: Value in Health)
Source: Value in Health - April 10, 2024 Category: International Medicine & Public Health Authors: Xue Li, Rui Li, Meixuan Li, Liang Yao, Harriette Van Spall, Kun Zhao, Yunxiang Chen, Feiyi Xiao, Qiang Fu, Feng Xie Tags: Systematic Literature Review Source Type: research
Testing the psychometric properties of 9 bolt-ons for the EQ-5D-5L in a general population sample
We aim to assess the psychometric performance and added value of nine existing bolt-ons (breathing problems, cognition, hearing, self-confidence, skin irritation, sleep, social relationships, tiredness and vision) for the EQ-5D-5L in a general population sample. (Source: Value in Health)
Source: Value in Health - April 8, 2024 Category: International Medicine & Public Health Authors: Fanni Rencz, Mathieu F. Janssen Source Type: research
The PICOTS-ComTeC Framework for Defining Digital Health Interventions: An ISPOR Special Interest Group Report
Digital health definitions are abundant, but often lack clarity and precision. We aimed to develop a minimum information framework to define patient-facing digital health interventions (DHIs) for outcomes research. (Source: Value in Health)
Source: Value in Health - April 1, 2024 Category: International Medicine & Public Health Authors: Zsombor Zrubka, Annette Champion, Anke-Peggy Holtorf, Rossella Di Bidino, Jagadeswara Rao Earla, Artem T. Boltyenkov, Masami Tabata-Kelly, Carl Asche, Anita Burrell Tags: ISPOR Report Source Type: research
Table of Contents
(Source: Value in Health)
Source: Value in Health - April 1, 2024 Category: International Medicine & Public Health Source Type: research
Editorial Board
(Source: Value in Health)
Source: Value in Health - April 1, 2024 Category: International Medicine & Public Health Source Type: research
Anti –Vascular Endothelial Growth Factor Drugs Compared With Panretinal Photocoagulation for the Treatment of Proliferative Diabetic Retinopathy: A Cost-Effectiveness Analysis
This study aimed to evaluate the cost-effectiveness of anti –vascular endothelial growth factor drugs (anti-VEGFs) compared with panretinal photocoagulation (PRP) for treating proliferative diabetic retinopathy (PDR) in the United Kingdom. (Source: Value in Health)
Source: Value in Health - March 26, 2024 Category: International Medicine & Public Health Authors: Matthew Walton, Laura Bojke, Mark Simmonds, Ruth Walker, Alexis Llewellyn, Helen Fulbright, Sofia Dias, Lesley A. Stewart, Tom Rush, David H. Steel, John G. Lawrenson, Tunde Peto, Robert Hodgson Tags: Economic Evaluation Source Type: research
